Omeros Corp (OMER) Stock Price & Analysis
Omeros Corp (OMER) rose 1.22% to USD 9.97 as of June 10, 2026 at 03:30 UTC, according to Nexqual real-time market data.
OMER last closed at USD 9.85; the session ranged USD 9.55–10.03 on volume of 1,543,789 shares. Market capitalization is $721.58M, with a 52-week range of USD 2.95–17.65 (NGM). Source: Nexqual, June 10, 2026 at 03:30 UTC.
Key Statistics (as of June 10, 2026 at 03:30 UTC)
| Price | USD 9.97 |
|---|---|
| Change | ▲ 1.22% (up) |
| Previous Close | USD 9.85 |
| Open | USD 9.86 |
| Day Range | USD 9.55 – 10.03 |
| 52-Week Range | USD 2.95 – 17.65 |
| Volume | 1,543,789 shares |
| Market Cap | $721.58M |
| Exchange | NGM |
Technical Analysis (OMER)
Nexqual's technical model rates OMER "SELL" based on 2 bullish and 5 bearish signals across 124 daily candles, as of June 10, 2026 at 03:30 UTC.
| Overall Signal | SELL |
|---|---|
| RSI (14) | 29.98 (oversold) |
| vs SMA50 | Below (USD 12.4) |
| MACD | -0.87 (negative) |
Analyst Ratings (OMER)
Wall Street analysts rate OMER "Buy" based on 1 analysts, with a mean price target of USD 40 (range USD 40–40), per Nexqual as of June 10, 2026 at 03:30 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 1 |
| Mean Target | USD 40 |
| High Target | USD 40 |
| Low Target | USD 40 |
| Buy / Hold / Sell | 1 / 2 / 0 |
Earnings (OMER)
| Next Earnings Date | 2026-08-13 |
|---|---|
| EPS Estimate | USD 0.27 |
| Revenue Estimate | $12.67M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2026-03-31 | USD 0.57 vs est -0.39 ▲ beat |
| 2025-12-31 | USD 3.14 vs est 2.24 ▲ beat |
| 2025-09-30 | USD -0.32 vs est -0.48 ▲ beat |
| 2025-06-30 | USD -0.53 vs est -0.55 ▲ beat |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Financials & Fundamentals (OMER)
| Total Revenue | $9.89M |
|---|---|
| Gross Margin | -190.49% |
| Operating Margin | -176.09% |
| Profit Margin | +871.02% |
| Current Ratio | 3.03 |
| Total Cash | $135.32M |
| Total Debt | $226.61M |
| Free Cash Flow | $181.02M |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Financial Health Score (OMER)
Nexqual rates Omeros Corp's overall financial health "Weak" across five dimensions, as of June 10, 2026 at 03:30 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Weak — Pre-revenue or very early stage |
| Balance Sheet | Mixed — $135M cash vs $227M debt |
| Cash Flow | Weak — Operating cash flow -$95M |
| Efficiency | Mixed — No data |
Ownership (OMER)
| Insider Ownership | +3.56% |
|---|---|
| Institutional Ownership | +44.42% |
| Shares Outstanding | 72.38M |
| Float | 69.80M |
| Short % of Float | +23.31% |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
Leadership (OMER)
Omeros Corp is led by Gregory A. Demopulos (age 66), Co-Founder, Chairman, CEO & President, per Nexqual as of June 10, 2026 at 03:30 UTC.
| Co-Founder, Chairman, CEO & President | Gregory A. Demopulos (age 66) |
|---|---|
| Chief Scientific Officer & VP of Science | George A. Gaitanaris (age 68) |
| Vice President of Human Resources | Peter W. Williams (age 57) |
Major Backers & Investors (OMER)
Notable institutional backers of Omeros Corp include Ingalls & Snyder LLC, UBS Group AG, Stifel Financial Corporation, according to Nexqual as of June 10, 2026 at 03:30 UTC.
Active Investors
| Investor | Stake |
|---|---|
| Ingalls & Snyder LLC | 4.92% |
| UBS Group AG | 3.23% |
| Stifel Financial Corporation | 2.53% |
| Fidelity | 1.41% |
| Corient Private Wealth LLC | 1.11% |
| Charles Schwab Investment Management, Inc. | 0.8% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 10.28% |
| Vanguard Group | 9.87% |
| State Street | 3.39% |
| Geode Capital | 2.42% |
Source: Nexqual, June 10, 2026 at 03:30 UTC.
From Omeros Corp's Latest SEC 10-K Filing (filed 2026-03-31)
Key Strengths & Strategy (as disclosed to the SEC)
- Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases.
- The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
- It also develops OMS1029 that has completed phase I clinical trials for mannan-binding lectin-associated serine protease 2 (MASP-2) and lectin pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders, as well as cocaine use disorder.
- In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; OncotoX-AML, to treat acute myeloid leukemia; and Targeted Complement Activating Therapy, for Multidrug-resistant organisms.
Source: SEC EDGAR 10-K, official filing. Curated by Nexqual.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| OCUL | Ocular Therapeutix, Inc. | USD 8.47 | ▲ 2.67% |
| KPTI | Karyopharm Therapeutics Inc. | USD 8.69 | ▼ 4.3% |
| PTCT | PTC Therapeutics, Inc. | USD 73.68 | ▲ 3.82% |
| MGNX | MacroGenics, Inc. | USD 3.91 | ▲ 0% |
| VNDA | Vanda Pharmaceuticals Inc. | USD 6.12 | ▲ 1.49% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 03:30 UTC. This page is informational and not investment advice.